Evidence Details for NRXN2
Basic Information Top
Gene Symbol: | NRXN2 ( FLJ40892,KIAA0921 ) |
---|---|
Gene Full Name: | neurexin 2 |
Band: | 11q13.1 |
Quick Links | Entrez ID:9379; OMIM: 600566; Uniprot ID:NRX2A_HUMAN; ENSEMBL ID: ENSG00000110076; HGNC ID: 8009 |
Relate to Another Database: | SFARIGene; denovo-db |
Sequences Top
>NRXN2|9379|nucleotide
ATGGCGTCCGGGAGCCGGTGGCGGCCGACACCGCCGCCGCTGCTGTTGCTGCTGCTGCTGGCGCTGGCGGCGCGCGCGGACGGCCTGGAGTTCGGCGGCGGCCCC
GGGCAGTGGGCTCGCTACGCGCGCTGGGCGGGCGCGGCGAGCAGCGGCGAGCTCAGCTTCAGCCTGCGCACCAACGCCACGCGCGCGCTGCTGCTCTACCTGGAC
GACGGCGGCGACTGCGACTTCCTGGAGCTGCTGCTGGTGGACGGCCGCCTGCGGCTGCGCTTCACGCTTTCGTGCGCCGAGCCGGCCACGCTGCAGCTGGACACG
CCGGTGGCCGACGACCGCTGGCACATGGTGCTGCTGACCCGCGACGCGCGCCGCACGGCGCTGGCGGTGGACGGCGAGGCCCGCGCCGCCGAGGTGCGCTCCAAG
CGGCGCGAGATGCAGGTGGCCAGCGACCTGTTCGTGGGCGGCATCCCGCCCGACGTGCGCCTCTCGGCGCTTACGCTGAGCACCGTCAAGTACGAGCCGCCCTTC
CGCGGCCTCTTGGCCAACCTGAAGCTGGGCGAGCGGCCCCCCGCGCTGCTGGGCAGCCAGGGCCTGCGCGGCGCCACCGCCGACCCGCTGTGCGCGCCCGCGCGC
AACCCCTGCGCCAACGGCGGCCTCTGCACCGTGCTGGCCCCCGGCGAGGTGGGCTGCGACTGCAGCCACACGGGCTTCGGCGGCAAGTTCTGCAGCGAAGAGGAG
CACCCCATGGAAGGTCCGGCTCACCTGACGTTAAACAGCGAAGTAGGGTCCTTACTGTTCTCCGAGGGGGGGGCCGGGAGAGGAGGAGCCGGCGATGTGCACCAG
CCAACAAAAGGCAAGGAGGAGTTTGTGGCGACCTTCAAAGGCAATGAGTTCTTCTGCTACGACCTGTCACACAACCCCATCCAGAGCAGCACTGATGAGATCACA
CTGGCCTTCCGCACCCTGCAACGCAACGGCCTGATGCTGCATACAGGCAAGTCGGCCGACTACGTCAACCTGTCCCTCAAGTCTGGGGCTGTCTGGCTGGTCATC
AACCTAGGCTCAGGTGCCTTCGAGGCCCTTGTGGAACCCGTCAATGGCAAGTTCAACGACAACGCCTGGCACGACGTCCGGGTCACCCGAAACCTGCGCCAGCAC
Show »
ATGGCGTCCGGGAGCCGGTGGCGGCCGACACCGCCGCCGCTGCTGTTGCTGCTGCTGCTGGCGCTGGCGGCGCGCGCGGACGGCCTGGAGTTCGGCGGCGGCCCC
GGGCAGTGGGCTCGCTACGCGCGCTGGGCGGGCGCGGCGAGCAGCGGCGAGCTCAGCTTCAGCCTGCGCACCAACGCCACGCGCGCGCTGCTGCTCTACCTGGAC
GACGGCGGCGACTGCGACTTCCTGGAGCTGCTGCTGGTGGACGGCCGCCTGCGGCTGCGCTTCACGCTTTCGTGCGCCGAGCCGGCCACGCTGCAGCTGGACACG
CCGGTGGCCGACGACCGCTGGCACATGGTGCTGCTGACCCGCGACGCGCGCCGCACGGCGCTGGCGGTGGACGGCGAGGCCCGCGCCGCCGAGGTGCGCTCCAAG
CGGCGCGAGATGCAGGTGGCCAGCGACCTGTTCGTGGGCGGCATCCCGCCCGACGTGCGCCTCTCGGCGCTTACGCTGAGCACCGTCAAGTACGAGCCGCCCTTC
CGCGGCCTCTTGGCCAACCTGAAGCTGGGCGAGCGGCCCCCCGCGCTGCTGGGCAGCCAGGGCCTGCGCGGCGCCACCGCCGACCCGCTGTGCGCGCCCGCGCGC
AACCCCTGCGCCAACGGCGGCCTCTGCACCGTGCTGGCCCCCGGCGAGGTGGGCTGCGACTGCAGCCACACGGGCTTCGGCGGCAAGTTCTGCAGCGAAGAGGAG
CACCCCATGGAAGGTCCGGCTCACCTGACGTTAAACAGCGAAGTAGGGTCCTTACTGTTCTCCGAGGGGGGGGCCGGGAGAGGAGGAGCCGGCGATGTGCACCAG
CCAACAAAAGGCAAGGAGGAGTTTGTGGCGACCTTCAAAGGCAATGAGTTCTTCTGCTACGACCTGTCACACAACCCCATCCAGAGCAGCACTGATGAGATCACA
CTGGCCTTCCGCACCCTGCAACGCAACGGCCTGATGCTGCATACAGGCAAGTCGGCCGACTACGTCAACCTGTCCCTCAAGTCTGGGGCTGTCTGGCTGGTCATC
AACCTAGGCTCAGGTGCCTTCGAGGCCCTTGTGGAACCCGTCAATGGCAAGTTCAACGACAACGCCTGGCACGACGTCCGGGTCACCCGAAACCTGCGCCAGCAC
Show »
>NRXN2|9379|protein
MASGSRWRPTPPPLLLLLLLALAARADGLEFGGGPGQWARYARWAGAASSGELSFSLRTNATRALLLYLDDGGDCDFLELLLVDGRLRLRFTLSCAEPATLQLDT
PVADDRWHMVLLTRDARRTALAVDGEARAAEVRSKRREMQVASDLFVGGIPPDVRLSALTLSTVKYEPPFRGLLANLKLGERPPALLGSQGLRGATADPLCAPAR
NPCANGGLCTVLAPGEVGCDCSHTGFGGKFCSEEEHPMEGPAHLTLNSEVGSLLFSEGGAGRGGAGDVHQPTKGKEEFVATFKGNEFFCYDLSHNPIQSSTDEIT
LAFRTLQRNGLMLHTGKSADYVNLSLKSGAVWLVINLGSGAFEALVEPVNGKFNDNAWHDVRVTRNLRQHAGIGHAMVNKLHYLVTISVDGILTTTGYTQEDYTM
LGSDDFFYIGGSPNTADLPGSPVSNNFMGCLKDVVYKNNDFKLELSRLAKEGDPKMKLQGDLSFRCEDVAALDPVTFESPEAFVALPRWSAKRTGSISLDFRTTE
Show »
MASGSRWRPTPPPLLLLLLLALAARADGLEFGGGPGQWARYARWAGAASSGELSFSLRTNATRALLLYLDDGGDCDFLELLLVDGRLRLRFTLSCAEPATLQLDT
PVADDRWHMVLLTRDARRTALAVDGEARAAEVRSKRREMQVASDLFVGGIPPDVRLSALTLSTVKYEPPFRGLLANLKLGERPPALLGSQGLRGATADPLCAPAR
NPCANGGLCTVLAPGEVGCDCSHTGFGGKFCSEEEHPMEGPAHLTLNSEVGSLLFSEGGAGRGGAGDVHQPTKGKEEFVATFKGNEFFCYDLSHNPIQSSTDEIT
LAFRTLQRNGLMLHTGKSADYVNLSLKSGAVWLVINLGSGAFEALVEPVNGKFNDNAWHDVRVTRNLRQHAGIGHAMVNKLHYLVTISVDGILTTTGYTQEDYTM
LGSDDFFYIGGSPNTADLPGSPVSNNFMGCLKDVVYKNNDFKLELSRLAKEGDPKMKLQGDLSFRCEDVAALDPVTFESPEAFVALPRWSAKRTGSISLDFRTTE
Show »
Evidence summary Top
Click the link of the category-specific score to view different category of evidences. The categories without any evidences are hidden by default.
Evidences | Syndromic Gene | GWAS | CNV | Linkage | Association | Expression | NGS de novo | NGS Mosaic | NGS Other | Low-Scale Gene Studies | Total |
---|---|---|---|---|---|---|---|---|---|---|---|
Score (No. of Studies) | No | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 0 (2) | 0 (0) | 0 (1) | 1 (1) | 12 (5) |
Syndromic Autism Gene Top
Genome-Wide Association Studies(By Ethnic Group) Top
CNV Studies Top
Linkage Studies Top
Low Scale Association Studies (by Ethnic Group) Top
Family Based Association Studies: 0
Reference | Source | Platform | #Families | Affecteds | Result | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
#Subjects (% Women) |
ADI-R | ADOS | Diagnosis | Age (range) |
IQ (range) |
||||||||
No Evidence. |
Case Control Based Association Studies: 1
Reference | Source | Platfrom | ASD Cases | Normal Controls | Result | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ADI-R | ADOS | Diagnosis | Age (range) |
IQ | #Subjects (% Women) |
Age (range) |
|||||
CAUCASIAN | |||||||||||
Koberstein JN, 2018_1 | Unknown | Life Technologies | - | - | ASD | - 3.3 to 15.2 years |
- | 214 (-) |
- 3.2 to 16.3 years | - | |
MIXED/OTHERS | |||||||||||
Wang J, 2018_1 | China | - | ASD | - - |
- | 1923 (12.48%) |
- - |
Large Scale Expression Studies Top
NGS de novo Mutation Studies Top
Reference | Case Number | Family Number | de novo Number | Title |
---|---|---|---|---|
Iossifov I, 2014 | 2508 | - | 1194 | The contribution of de novo coding mutations to autism spectrum disorder. |
Li J, 2017 | 536 | - | 22 | Targeted sequencing and functional analysis reveal brain-size-related genes and their networks in au |
NGS Mosaic SNV Studies Top
NGS Other Studies Top
Reference | Source | Platform | ADI-R | ADOS | Diagnosis | Family | Affected | Validation Method | ||
---|---|---|---|---|---|---|---|---|---|---|
Total | Simplex | Multiplex | ||||||||
Cukier HN, 2014 | - | Illumina HiSeq 2000 | ASD | 40 | - | - | 100 | HumanExome BeadChip or Sanger sequencing |
Low Scale Gene Studies Top
Contact Us if you are an author of a study regarding this gene and do not find your study in this table or find errors in the representation of your study details.